Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says – CNBC
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says CNBC Lilly and Eisai Diverge on Alzheimer’s Drugs Long-Term Usage Bloomberg Eisai, Biogen make case for long-term…